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Though the total number of tuberculosis (TB) cases reported in the United States (US) is 
decreasing, persistently high incidence among foreign-born individuals has slowed 
progress towards national TB elimination.  Reducing the overall incidence of TB the US 
will require enhanced diagnosis and treatment of active TB among the foreign-born, as 
well as targeting the pool of latently infected individuals who represent an important 
source of future TB cases.  This analysis examines three important aspects of controlling 
TB in foreign-born individuals. The first study evaluates of efforts by Baltimore City 
Health Department (BCHD) to screen and treat refugees, non-refugee foreign-born 
individuals and other patient groups for latent tuberculosis infection (LTBI) and 
describes factors associated with patient compliance with LTBI evaluation. The second 
study evaluates post-arrival screening and treatment of high-risk (Class B) immigrants 
referred to BCHD and assesses whether recent efforts to conduct additional sputa 
testing on all Class B immigrants resulted in enhanced TB case finding.  The third study 
reviews the importance of LTBI testing and treatment of the foreign-born, and examines 
ways to equip health departments to complete this important pillar of the US strategy 
for TB elimination.  The results of these studies suggest that local health department 
efforts to screen and treat foreign-born individuals for tuberculosis and LTBI can be 
effective in reducing the overall burden of illness within the community.  However, 
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CHAPTER 1: BACKGROUND AND INTRODUCTION 
 
 
Overview of the Current Epidemiology of Tuberculosis in the United States 
 
For the last 20 years, the United States has seen a steady decrease in the annual number 
of tuberculosis (TB) cases.  In 2013, fewer than 10,000 new TB cases were reported across 
the country—the lowest number of incident cases since reporting began in the 1950s.[1]   
Despite this welcome progress, the percent reduction in new TB cases has slowed in 
recent years and the current incidence of TB cases in the U.S. (3.0 per 100,000 
population) still exceeds CDC's TB elimination goal of having <1 case per 1 million 
population.[1] The CDC has estimated that at the rate the TB incidence has been 
declining in recent years, it may take more than 90 years to achieve TB elimination. [2]  
 
One of the biggest obstacles to eliminating TB from the United States is persistently 
high incidence of TB among the foreign-born, which is 13 times greater than the 
incidence among U.S.-born individuals.[1]  The majority (65%) of U.S. TB cases now 
occur among the foreign-born and efforts to reduce incidence in this group have been 
slow compared to U.S. born. Since 1993, the annual incidence of TB among U.S.-born 
individuals has decreased by more than 80%., from 7.4 cases per 100,000 to 1.4 per 
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100,000.  But incidence among the foreign-born has been consistently higher—falling 
from 34 cases per 100,000 in 1993 to 15.9 cases per 100,000 in 2012 (a 53% decline) 
(Figure 1). 
 
The contribution of foreign-born to TB rates in these states and others are likely to 
continue to increase, as both the number of and percentage of the US population that is 
foreign-born persons born abroad has grown steadily since 1970 (Figure 2). Each year, 
approximately 1 million new immigrants and 173 million foreign-born non-immigrant 
visitors enter the United States (Table 1).  Additionally, it is estimated that 11.7 million 
foreign-born, unauthorized immigrants currently live in the US.[3] Currently, the states 
that report the greatest number of TB cases--California, Texas, New York, and Florida—
are also those with the highest percentage of foreign-born persons.[1, 4] Combined, 
these four states accounted for 51.3% of all TB cases reported in 2013 and over half of 
the number of foreign-born individuals living in the U.S. in 2010.  Each of these states 






US Efforts to Reduce TB among the Foreign-Born 
 
Pre-Arrival Screening of Immigrants 
 
To reduce the chances that TB will be introduced from abroad, the US requires that 
individuals applying to immigrate to the US undergo a pre-arrival medical exam that 
includes TB screening.  These exams are conducted overseas by US Department of 
State-appointed panel physicians. The panel physicians conduct TB evaluations 
according to technical instructions (TIs) developed by the CDC.  These instructions 
require different levels of screening, depending on a patient’s age and the TB incidence 
in the country from which he/she is emigrating (Table 2).  
 
In 2007, CDC published new TIs that included additional screening requirements.  
Under the revised TIs, the panel physicians must conduct the following: 1) TST or IGRA 
tests for children (age 2-14) from countries with WHO-estimated incidence ≥20 
cases/100,000 population; 2) cultures in addition to smears when sputa testing is 
indicated; and 3) drug-susceptibility testing for positive isolates.[6]  A recent analysis 
conducted by the CDC estimates that 1,100 cases of TB were diagnosed among 
applicants in 2012 using the new TIS.[6] Among those cases, approximately 60% of all 
cases were smear-negative/culture-positive.[7]  
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Under the current TIs, individuals with evidence of untreated, active, contagious TB are 
considered to have a Class A condition.  Class A applicants are not allowed to enter the 
United States unless they receive a medical waiver.   Individuals with some evidence of 
radiographic evidence of TB (including extrapulmonary TB that is not laryngeal or 
pleural), but negative smears and cultures, are designated as Class B1. Individuals who 
have a positive TST (≥5 mm if individual is contact of known TB case, ≥10 mm for all 
others) or IGRA, but no other signs of TB are classified as B2.  Individuals who are a 
recent contact of a known tuberculosis case (usually, contacts of individuals who have 
received an A classification) are designated as B3.  Class B immigrants are allowed to 
enter the US, but are instructed to undergo follow-up examinations within 30 days of 
arrival in the US.  
 
Post-Arrival Screening and Treatment  
 
The US also maintains programs for post-arrival screening and treatment of foreign-
born individuals.  When immigrants with Class A and Class B medical conditions enter 
the United States, CDC notifies health departments of their arrival, so that they may 
oversee the follow-up examinations of these individuals. In 2009, health departments in 
50 states and the District of Columbia were notified of the arrival of 23,321 Class B and 
20 Class A (with waiver) immigrants in need of post-arrival tuberculosis examinations.  
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According to the CDC, across the country, health departments provided follow-up 
examinations for a median of 75.4% of all notifications for immigrants with suspected 
tuberculosis classifications.[8]   
 
There are additional efforts to provide post-arrival TB screening for the subset of 
immigrants that enter the US as refugees.  Like other immigrants, refugees undergo a 
pre-arrival medical examination to determine their eligibility to enter the United States.  
Those cleared to travel to the US receive a subsequent evaluation upon arrival in the 
US, which includes tuberculosis screening.   
 
Targeted Testing and Treatment of LTBI  
 
A number of authoritative groups including the American Thoracic Society, the 
Institute of Medicine and the U.S. Centers for Disease Control and Prevention (CDC) 
have recommended that there be dedicated programs for testing and treatment of 
foreign-born individuals for latent TB infection (LTBI). [9-11] Accurate diagnosis and 
effective treatment of latent tuberculosis infection (LTBI)— having either immunologic 
or radiographic evidence of TB infection, but no evidence of active TB diseases—can 
reduce the incidence of TB by shrinking the pool of individuals who represent an 
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important source of future TB cases.   A 9 month course of isoniazid (INH) 
chemoprophylaxis—has been shown to reduce the risk of active TB in patients with 
LTBI almost 90%.[12]  
 
Foreign-born individuals have been identified as a priority for LTBI screening and 
treatment, as they are at high-risk group for progression to TB.  Studies suggest that a 
major contributor to TB cases in the US is the reactivation of infections acquired abroad. 
Eighty percent of active TB cases reported in the U.S. have been attributed to 
reactivation of prior infection, rather than newly transmitted infection.[13] The rate of 
reactivation TB among persons with latent TB infection (LTBI) is higher among foreign-
born persons than among persons born in the United States.  It has also been shown that 
the risk of reactivation persists long after arrival in the United States, even though LTBI 
screening guidelines suggest targeting only those individuals who have been in the 
country for fewer than 5 years. [14]   
 
Though targeted testing and treatment of LTBI in foreign-born, has been identified as a 
necessary step to achieve U.S. TB elimination goals, it remains an overlooked 
component of TB control efforts US.[15] Current guidelines for pre-arrival medical 
screening do not include LTBI evaluation for adults or other non-immigrant foreign-
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born visitors that enter the US.  Moreover, efforts to screen and treat foreign-born 
individuals after arrival in the US are limited.  US health departments, which conduct 
the majority (~80%) of LTBI treatment that occurs in the US, have largely not been able 
to maintain dedicated programs to test and treat foreign-born individuals for LTBI.[16, 
17]   Though health departments may require post-arrival LTBI evaluations of the 
minority of immigrants that enter the US with refugee status, funding restrictions in 
some areas have limited the type of screening and treatment health departments are 
able to conduct.[18, 19]  
 
Current Approaches for Diagnosing LTBI 
 
Traditionally, diagnosis of LTBI relied on use of the tuberculin skin test (TST).  Though 
this test is still widely used, TSTs are subject to a number of shortcomings, including 
cross-reactivity with Bacillus Calmette-Guérin (BCG) vaccine and other Mycobacterium 
infections.   There are also operational challenges associated with administering TST.  
Interpretation of TST results can be clinically subjective, as it requires healthcare 
workers to visually measure the size of induration and interpret the results. Guidelines 
for what is considered a positive result vary by country and the presence and a number 
of factors, including a patient’s immune status.  Test administration error can also cause 
the size of an induration to vary.  Administering the TST to an individual requires that 
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he/she make at least two visits to a health care provider.  When individuals are subject 
to routine screening, two-step testing may be required, which would require an 
additional healthcare visit to have a TST result read.  
 
In recent years, newer in-vitro methods—called Interferon-Gamma Release Assays 
(IGRAs)—have become available for diagnosing LTBI.  QuantiFERON-TB Gold (QFT-
G), QuantiFERON-TB Gold In-tube (QFT-GIT) and the T-SPOT.TB are the three 
commercially-available IGRA tests that have been approved by the FDA as indirect 
tests for Mycobacterium tuberculosis infection.  IGRAs offer a number of potential 
advantages over TSTs in diagnosing LTBI.  First, unlike the TST, IGRAs have been 
shown to be specific to infection with M. tuberculosis and do not appear to be 
influenced by BCG vaccination.  Second, interpreting IGRA test results is less subjective 
than for the TST. Third, administering an IGRA require only one health care visit 
(versus 2 visits for TST screening of healthcare workers or 3 visits if two-step TST 
screening is required). Fourth, IGRA test results can be available 24 hours (versus 2-3 
days for TST). In light of these advantages, a number of countries have incorporated 




Despite a number of potential advantages, there are also a number of drawbacks 
associated with IGRAs.  Though several systematic reviews have demonstrated that 
IGRAs generally have comparable sensitivity and enhanced specificity when compare 
to TST, there is evidence that IGRA test performance may vary.  Different commercial 
IGRA tests have been shown to have different sensitivities.[21] A small number of 
studies have found lower IGRA sensitivity when used in high and intermediate TB-
burden settings[22, 23] and when used to screen certain populations (e.g., children[22, 
24] and HIV+ individuals[25, 26]).  Others studies suggest there may be significant 
within subject variability of IGRA tests when used to serially test individuals.[27] 
 
Baltimore City Health Department’s Role in Screening and Treating Foreign-born Individuals 
for TB and LTBI 
 
TB remains an important public health issue in Baltimore City, Maryland. The annual 
incidence of reported cases of active TB (3.4 cases per 100,000 in 2013) exceeds the 
national average, with a large proportion of active TB cases attributable to foreign-born 
individuals (62% in 2013; BCHD unpublished data). [28, 29] As part of the regional TB 
control strategy, the Baltimore City Health Department Tuberculosis (BCHD) TB 
program has historically provided medical evaluation and care services free of charge 
to Baltimore City residents who are diagnosed with active TB and LTBI.  
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Overview of this Study 
 
This study describes three important aspects of post-arrival screening and treatment of 
foreign-born individuals for tuberculosis and LTBI by local health departments.  
Chapter 2 presents an analysis of efforts by Baltimore City Health Department (BCHD) 
to screen and treat refugees, non-refugee foreign-born individuals and other patient 
groups for LTBI.  The aim of Chapter 2 is to provide a better understanding of the 
factors associated with patient compliance with LTBI evaluation in order to inform 
patient care for epidemiologically important populations, such as refugees.  
 
Chapter 3 contains an analysis of post-arrival screening and treatment of Class B 
immigrants referred to BCHD for follow-up examination.  This study describes how 
Class B immigrants were screened in practice and analyzed the extent to which testing 
was conducted according to existing protocols.  This study also aimed to evaluate 
whether recent efforts to conduct additional sputa testing on all Class B immigrants 
resulted in enhanced TB case finding.   
 
Chapter 4 reviews the importance of LTBI testing and treatment of the foreign-born, 
and discusses ways to equip health departments to complete this important pillar of the 
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US strategy for TB elimination.  This chapter examines the policy landscape 
surrounding US TB control programs and details current and future challenges that 

















Figure 1: Number and incidence of tuberculosis (TB) cases among U.S.-born and 
foreign-born persons, by year reported — United States, 2000–2013 
 


























Table 1: Annual Influx of Immigrants and Non-Immigrant Visitors to the United 
States* 





Refugees Asylees Parolees 
2003 703,542 34,362 10,402 4,196 180,500,000 
2004 957,883 61,013 10,217 7,121 180,200,000 
2005 1,122,257 112,676 30,286 7,715 175,300,000 
2006 1,266,129 99,609 116,845 4,569 175,100,000 
2007 1,052,415 54,942 81,183 1,999 171,300,000 
2008 1,107,126 90,030 76,362 1,172 175,400,000 
2009 1,130,818 118,836 58,532 2,385 162,600,000 
2010 1,042,625 92,741 43,550 1,592 159,700,000 
2011 1,062,040 113,045 55,415 1,147 158,500,000 
2012 1,031,631 105,528 45,086 758 165,500,000 
Median per 
year 
1,057,228 96,175 50,251 2,192 173,200,000 








Table 2: Pre-Arrival TB Screening Requirements for Individuals Applying for 
Immigration to the US 










Sputa testing if: CXR 
with findings 
suggestive of 
tuberculosis, or has 
signs and symptoms 
of tuberculosis, or 
HIV positive  
N/A 
2-14 years of age, 
from countries with 






TST or an IGRA 
Chest xray: if TST is 
≥10mm or IGRA is 
positive, or has signs 
and symptoms of TB, 
or HIV infection 
Sputa testing: if 
CXR suggestive 
of tuberculosis, 




<2 years of age, from 
countries with TB 





Chest xray, TST or 
IGRA testing, and 
sputa testing: if signs 
and symptoms of TB, 
or HIV infection 
 
N/A 
<15 years, from 







Sputa testing: if HIV+ 
or abnormal CXR 
 
N/A 
Source: CDC. CDC Immigration Requirements: Technical Instructions for Tuberculosis Screening and 
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CHAPTER 2: SCREENING AND TREATING REFUGEES AND OTHER 
PATIENT GROUPS IN BALTIMORE CITY FOR LTBI 
 
 
Analysis of latent tuberculosis infection treatment adherence among refugees and 
other patient groups referred to the Baltimore City Health Department TB clinic, 
February 2009 -- March 2011 
Jennifer B. Nuzzo1, Jonathan E. Golub2, Patrick Chaulk3, Maunank Shah2 
 
1 Johns Hopkins University School of Public Health, Baltimore, Maryland and UPMC Center for 
Health Security 
2 Johns Hopkins University School of Medicine, Baltimore, Maryland 
3 Baltimore City Health Department, Baltimore, Maryland 
 







Background:  We sought to determine the proportion of refugee patients at the 
Baltimore City Health Department Tuberculosis program (BCHD-TB) successfully 
completing LTBI treatment, as compared to other referral groups, and to identify factors 
associated with treatment completion.  
Design: Retrospective cohort analysis of individuals referred to BCHD-TB program for 
LTBI care between February 1, 2009 and March 31, 2011. 
Results: Among 841 patients evaluated by BCHD-TB and diagnosed with LTBI, 81% of 
refugees, 50% of non-refugee foreign-born, and 35% of US-born patients completed 
LTBI treatment.   In multivariate analysis, refugees had greater odds of LTBI treatment 
completion (Adjusted Odds Ratio: 7.2; 95%CI: 4.2-12.4, p<0.001) compared to US-born 
individuals adjusting for age, gender, and treatment regimen.  
Conclusions: Overall, LTBI treatment completion remains suboptimal.  At BCHD-TB, 
LTBI treatment completion was significantly higher among refugees than other referral 
groups. Additional efforts are needed to optimize LTBI care, and future efforts may 







The prevention of active tuberculosis (TB) disease through the identification and 
treatment of individuals with latent tuberculosis infection (LTBI) is a key component of 
the United States (US) national strategy to eliminate tuberculosis.22  While the annual 
incidence of active TB has continued to decline in the US, national rates (3.2 per 100,000) 
exceed the goal for TB elimination (less than 1 case per 100,000).20  Reactivation of LTBI 
represents a significant source (>70%) of new cases of active TB reported in the US, 
especially among foreign-born individuals.23-25  Consequently, the US Centers for 
Disease Control and Prevention (CDC) recommends targeted testing and treatment of 
individuals at highest risk for TB infection, such as recent immigrants from TB-endemic 
regions of the world, including refugees and asylees. 11  
 
Baltimore City, Maryland, is an urban environment, population approximately 620,000, 
in which TB remains an important public health issue. The annual incidence of reported 
cases of active TB (3.5 cases per 100,000 in 2012) exceeds the national average, with a 
large proportion attributable to foreign-born individuals (36% in 2012).20,21  As part of 
the regional TB control strategy, the Baltimore City Health Department Tuberculosis 
(BCHD) TB program has historically provided medical evaluation and care services free 
of charge to Baltimore City residents with LTBI or active TB disease.  With respect to 
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LTBI, community sources who suspect that their patients are infected with M. 
tuberculosis, may refer patients with positive test results (typically individuals with a 
positive tuberculin skin test [TST]) to the BCHD TB program for evaluation and, if 
indicated, treatment.  BCHD receives nearly 500 such referrals each year from 
heterogeneous community sources including immigration programs, drug treatment 
programs, homeless services, and federally qualified health centers (FQHC).  
 
The largest source of patient referrals to the BCHD TB program for LTBI care is the 
state’s refugee health program, which is administered by a local FQHC.  Each year the 
State of Maryland screens ~1100 new refugees for M. tuberculosis infection with either a 
TST or Interferon-gamma-release-assay (IGRA), of which approximately 40% of 
individuals are sent to local health departments for follow-up evaluations for a positive 
test result.  Refugees referred to the BCHD TB clinic frequently come from countries 
with high incidence of TB and, therefore, represent a high priority group for LTBI 
screening and treatment within the city. 
 
Adherence to LTBI treatment is an important determinant of the success of local TB 
control efforts.  A number of studies have examined acceptance and adherence to 
treatment among patients in the United States.  Overall, LTBI treatment completion is 
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low and has been reported to depend on a variety of social, demographic and clinical 
factors.26-30  Few studies have addressed completion rates specifically among refugee 
populations; two studies from outside of the United States (Canada and Australia) 
reported that 49% and 44% of refugee immigrants (respectively) completed a full course 
of prescribed LTBI treatment.31,32  LTBI treatment success among refugees in the United 
States has not been previously evaluated.   
 
Our goal was to improve understanding of refugee care within Baltimore City by 
analyzing the proportion of refugees referred to BCHD for suspected LTBI that 
complete LTBI treatment.  We compared LTBI evaluation and treatment between 
refugees and other referral groups within Baltimore City, and evaluated factors 
associated with successful treatment completion.  A better understanding of the of the 
factors associated with patients’ reporting to the health department for evaluation and 









We performed a retrospective analysis of a cohort of individuals who were referred to 
the BCHD TB program for LTBI care between February 1, 2009 and March 31, 2011.  
Patients are referred to the BCHD TB program for LTBI care on the basis of a positive 
TST or Interferon gamma release assay (IGRA) test result. All individuals referred to the 
clinic for LTBI evaluation and care were included; individuals with confirmed or 
suspected active TB disease and their close-contacts were excluded from this analysis.  
 
LTBI Services at BCHD 
We reviewed information contained in the BCHD TB Program electronic database 
(Microsoft Access 2003) and in patients’ clinic charts to obtain all clinical and 
demographic data analyzed in this study. Age, sex, foreign-born status and country of 
origin information are collected at time of referral for all patients who are referred to 
BCHD TB program.   Individuals that adhere to an initial LTBI evaluation appointment 
are interviewed by BCHD TB program staff for signs and symptoms of active TB, 
medical history including TB risk factors, and demographics.  All individuals receive a 
chest x-ray and blood is drawn for liver chemistries; all patients are offered HIV testing.  
Prior to 2010, BCHD TB ClinicBCHD TB Program staff diagnosed LTBI based on TST or 
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IGRA results available from the referral source with no further LTBI testing; beginning 
in early 2010, BCHD performed additional Quantiferon-Gold-In-Tube (QFT-GIT) test on 
all individuals referred for a positive TST, and determined the final diagnosis of LTBI 
based on both test results.  Individuals with discordant QFT-GIT and TST results were 
diagnosed with LTBI based on an individualized assessment that included evaluating 
BCG status, quantitative test results, and other TB risk factors.  Individuals with signs 
and/or symptoms of active TB disease receive further evaluation that includes sputum 
microscopy and culture and other testing as needed.  Individuals diagnosed with LTBI 
are asked to return for a follow-up visit for treatment initiation. 
 
All patients diagnosed with LTBI in whom active TB has been excluded are prescribed 
treatment according to current treatment guidelines—either a 9 month course of 
isoniazid (INH9) or a 4 month course of rifampin (RIF4).22  The choice of drug treatment 
regimen (INH9 or RIF4) is based on the judgment of the TB clinician based on a 
patient’s co-morbidities and potential for drug-drug interactions to occur.  LTBI 
treatment initiation was defined as adherence to a follow-up visit at which medications 
were dispensed; all medications were provided at the clinic, free of charge.  The BCHD 
TB Clinic makes up to three additional attempts to reschedule an appointment in the 
event that a patient misses their scheduled visit. After treatment initiation, medications 
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are dispensed by BCHD-TB program staff at monthly clinic appointments.  Overall, 
individuals were considered to have completed treatment if their clinical records 
indicated that they completed at least 6 months of INH or at least 3 months of RIF and 
they showed up at BCHD to pick up a final allotment of medicine; we assumed that 




We summarized clinical and demographic factors present among patients who were 
referred to and/or examined by the BCHD TB program for suspected LTBI.  We 
examined the association of these factors with patients’ adherence to LTBI evaluation, 
treatment initiation, and treatment completion using logistic regression.  Variables were 
included in multivariate logistic regression analysis based on statistical significance in 
univariate analysis and/or clinical relevance.  We used likelihood ratio tests to 
determine overall p-values for variables included in our regression analyses that had 
more than two categories.  Categorical data were also analyzed using Chi square (χ2) 
and continuous variables were analyzed using a non-parametric k-sample test of 





Ethics committees at the Johns Hopkins University School of Medicine (Baltimore, USA) 
and the Baltimore City Health Department approved this research.  This study received 
a waiver of informed consent. 
 
Results 
Referrals and Evaluations 
A total of 1,357 patients were referred to the BCHD TB program for LTBI care on the 
basis of a positive TST or IGRA during the study period (Figure I).  Refugees from the 
State of Maryland’s Refugee Health Program accounted for 35% (473/1357) of patients 
and were the largest single source of patient referrals to the BCHD TB Program for LTBI 
care; the majority of refugees were of Nepalese or Bhutanese origin (Table I).  Non-
refugee foreign-born individuals referred from other community sources accounted for 
30% (397/1357) of patients referred to the BCHD TB Program for LTBI care, while US-
born patients accounted for 36% (487/1357) of patient referrals.  Among US-born 
patients, drug treatment programs and community clinicians accounted for the most 




Seventy-five percent [1,019/1357; 95% Confidence Interval (CI) 73%-77%] of all patients 
referred to the BCHD TB Program adhered to an initial clinic appointment and 
completed an LTBI evaluation.   Adherence to the initial LTBI evaluation appointment 
differed by referral source: 90% (427/473; 95% CI 87%-93%) of patients referred via the 
State’s Refugee Health program, 71% (281/229; 95% CI 59%-68%) of non-refugee 
foreign-born and 64% (311/487; 95% CI 59%-68%) of US-born patients completed an 
evaluation (p<0.001). 
 
Table I shows additional demographic and clinical characteristics of refugee, non-
refugee foreign-born, and US-born patients who were referred to and evaluated at the 
BCHD TB Clinic for TB.  
 
LTBI Diagnosis and Treatment Initiation 
Among all patients evaluated by BCHD TB Program staff, 83% (841/1019; 95% CI 80%-
85%) were ultimately diagnosed with LTBI during the study period (Figure I).  
Respectively, the proportion of refugees, non-refugee foreign-born and US-born 
patients who were diagnosed with LTBI was 86% (366/427; 95% CI 82%-89%), 81% 
(229/281; 95% CI 76%-86%), and 79% (246/311; 95% CI 74%-83%)(p=0.056).  
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Overall, we found that 78% percent (652/841; 95% CI 75%-80%) of all patients diagnosed 
with LTBI returned to the BCHD TB Program to initiate treatment. There was no 
difference in initiation of treatment between men (78%; 394/505; 95% CI 74%-82%) and 
women (77%; 258/336; 95% CI 72%-81%; p=0.675), but those initiating treatment were 
younger [median age 34; interquartile range (IQR) 22-47] compared to those that did not 
initiate (median age 39; IQR 29-51; p=0.016).   Information on treatment regimen was 
available for 646/652 patients who initiated treatment for LTBI.  Among patients 
diagnosed with LTBI, treatment initiation was highest among refugees (91%; 333/366; 
95% CI 88%-94%) compared with non-refugee foreign-born (66%; 152/229; 95% CI 60%-
72%) and US-born patients (68%; 167/246; 95% CI 62%-74%; p<0.001)(Figure I and Table 
II).   
 
Among all patients who initiated therapy, 58% (379/646) were prescribed RIF4 and 41% 
(267/646) were prescribed INH9 (Table III).  Treatment regimen differed with 
immigration status.   Sixty-six percent (220/331; 95%CI 61%-72%) of refugees who 
initiated treatment were treated with RIF4 (Table II), compared to 68% (101/149; 95%CI 
60%-75%) of non-refugee foreign-born individuals and 35% (58/166; 95% CI 28%-48%) 




In multivariate analysis we found that the odds that patients with LTBI would initiate 
treatment differed depending on immigration status and age (Table III).  Refugees had a 
significantly higher odds of initiating treatment as compared with US-born individuals 
(AOR= 4.4; 3.31-5.9; p<0.001), whereas, the odds that non-refugee foreign-born 
individuals would initiate treatment was not significantly different than that of US-born 
patients (AOR= 1.2; 0.89-1.6; p=0.264).  We also found that the youngest patients (ages 0-
14 years) had significantly higher odds of initiating treatment as compared with the 
reference group (patients ages 25-44) (AOR=2.5; 1.6-3.9; p<0.001).  We found no 
evidence of a difference in treatment initiation between males and females in any of the 
three immigration status groups (Table 3)(AOR= 0.93; 0.67-1.3; p=0.675). 
 
LTBI Treatment Completion 
Overall, only 495 out of the 841 (59%; 95% CI 55%-62%) patients who were evaluated by 
BCHD TB Program staff and diagnosed with LTBI successfully completed their 
treatment (Figure I).   The overall proportion of individuals who were diagnosed with 
LTBI that went on to complete treatment differed by immigration status and was 81% 
(296/366; 95% CI 76%-85%) among refugees, 50% (113/229; 95% CI 43-65%) among non-
refugee foreign-born, and 35% (86/246; 95% CI 29%-41%) among US-born (p<0.001) 
(Figure 1).   
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When examining only those that initiated LTBI treatment, we found that the overall 
proportion of individuals who successfully completed LTBI therapy was 76% (495/652; 
95%CI 72%-79%) (Figure I and Table II).  Among those initiating therapy, refugees were 
significantly more likely to complete treatment (89%; 296/333; 95% CI 85%-92%) as 
compared with US-born patients (52%; 86/167; 95% CI 44%-59%) and compared to non-
refugee foreign-born (75%; 113/152; 95% CI 67%-81%) (p<0.001).  This association was 
observed even after we adjusted for differences in age, gender and treatment regimen 
(AOR 7.2; 4.2-12; p<0.001; Table III). Non-refugee foreign-born patients had a lower 
percentage of treatment completion compared to refugees (p<0.001), but had increased 
odds of completing treatment as compared with US patients (AOR: 2.8; 1.6-4.9; p<0.001). 
 
Among patients initiating LTBI therapy, 80% (302/378; 95% CI 75%-84%) of those 
prescribed RIF4 completed their treatment compared to 73% (193/266; 95% CI 67%-78%) 
of those on INH9 (p= 0.030); however, this difference was not found to be significantly 
different in multivariate analysis when adjusting for age, gender, and immigration 
status (AOR: 1.1; 0.68-1.7; p=0.725).  Furthermore, we did not find any evidence that of a 
difference in completion between patients receiving different treatment regimens in our 
stratified analysis shown in Table 2.  Similarly, we found that patients completing 
treatment were younger (median age 32; IQR 20-45) compared to those failing to 
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complete treatment (median age 40; IQR 27-50; p= 0.013), but we did not find an 
association between age and treatment completion in multivariate analysis.  
 
Discussion  
Programs to screen foreign-born individuals for LTBI, like those in Baltimore City, are 
an important component of broader TB control goals.  The majority of new TB cases 
reported in the United States occur among foreign-born individuals. In 2011, the 
incidence of TB was 12 times greater among foreign-born individuals in the US than it 
was for individuals born in the US.33  Therefore, efforts to diagnose and treat LTBI 
among this high-risk group offer an important opportunity to prevent active TB cases 
from occurring.   
 
Within Baltimore City, refugees represent a high-risk group in whom LTBI care is 
particularly important.  Our findings suggest that only 81% of refugees diagnosed with 
LTBI by BCHD-TB program successfully complete therapy.  Nonetheless we found that 
treatment completion among refugees was significantly higher than in other foreign-




Overall, LTBI treatment completion at BCHD was relatively low (59%), but these results 
are consistent with those from other settings in the US.28,30  Interestingly, we found that 
a major barrier to LTBI care was treatment initiation.  Despite adherence to an initial 
clinic visit, over 20% of individuals evaluated by BCHD who were diagnosed with LTBI 
failed to return for a follow-up visit for treatment initiation.  The reasons for this finding 
are unclear, but we found that refugees were far more likely to return for LTBI 
treatment (91%) compared to both US-born (68%) and non-refugee foreign-born 
patients (66%).   
 
We examined factors associated with successful LTBI care and found that immigration 
status was the strongest predictor of LTBI treatment completion.  Refugees treated by 
the BCHD TB Program were seven times more likely to complete treatment compared 
to US-born individuals referred to BCHD with LTBI. We did not find compelling 
evidence that treatment completion varied according to patient gender or treatment 
regimen. Although there was some evidence of increased treatment completion among 
those patients who were treated with the shorter rifampin regimen, this association was 




This analysis is subject to several limitations.  First, we assumed that patients who 
regularly reported to BCHD to pick up LTBI medications complied with treatment.  
Therefore, our outcome of interest (treatment completion) may be subject to 
misclassification bias if patients did not consume medicines as prescribed.  Second, 
because this was a retrospective review, we were unable to conduct patient interviews 
to ascertain the health-system or patient-specific factors associated with non-adherence 
with clinic visits. Third, we also had limited data on other factors that have been shown 
to effect treatment completion in other settings, such as patients’ comorbidities (e.g., 
substance abuse, general health status) and socioeconomic data (e.g., housing or 
employment status).34 Therefore, we cannot make any judgments about differences in 
rates of adverse outcomes or other important factors other than the demographic 
variables discussed here that may have been related to whether or not a patient 
complied with treatment. Despite these limitations, this study does have a number of 
strengths.  To our knowledge it is one of the first to evaluate LTBI evaluation and 
treatment among refugees in the US.  Also, the number of patients included in this 
analysis is larger than many other published studies that have examined LTBI treatment 




The findings of this analysis are important for public health programs for two main 
reasons.  First, we found that adherence to LTBI evaluation and treatment among all 
patient groups remains suboptimal. Long duration of treatment, language barriers, and 
need for frequent clinic visits may represent possible obstacles for patients to 
successfully complete LTBI therapy.  Further research is urgently needed to determine 
the health system and patient factors associated with lack of LTBI treatment completion 
among refugees.  Second, the significant observed differences in adherence to LTBI 
evaluation and treatment among refugees, non-refugee foreign-born, and US-born 
individuals suggests that TB programs may require different strategies to optimize LTBI 
care among different groups of patients.  For example, US-born referrals to BCHD for 
LTBI care were largely from drug treatment programs or the Department of 
Corrections—groups that have historically been shown to have low adherence to 
treatment.  Closer collaborations with health providers or staff at these referral sites 
may be required to improve adherence to LTBI appointments and treatment.    
 
We cannot say with certainty why refugees had higher rates of compliance with LTBI 
evaluation and treatment than other patients.  One explanation may be different 
administrative mechanisms that oversee healthcare for refugee patients as compared 
with other foreign-born individuals. In Maryland, a dedicated program exists for 
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screening and treating immigrants who arrive in the United States as refugees. The 
Maryland State Refugee Resettlement Program provides social services, financial and 
medical assistance including health screenings, health insurance, and access to primary 
care providers through FQHCs to refugees resettled in Maryland. These services are 
available for all refugees for eight months after their arrival in the US.  In some 
circumstances, refugees may be eligible for state-based services for an extended period 
of time (up to five years). This support may contribute to enhanced patient follow-up 
and/or ease other life demands that may prevent other immigrant patients or US-born 
individuals from accessing care.  As such, the provision of these state-based support 
services may contribute to the higher LTBI treatment completion rates seen in our 
study.  Differences in cultural perceptions may also play a role, as it is possible that 
refugees have enhanced of awareness of TB and the need for treatment due to high 
levels of TB disease in refugee camps. Though compliance with LTBI screening and 
treatment is not a requirement for resettlement, though it is possible that refugees have 
the perception that compliance is necessary to continue to receive benefits.   
 
Historically, BCHD has provided all LTBI evaluation, diagnosis and treatment services 
for refugees living in Baltimore City.  However, as of late 2012, BCHD no longer 
provides LTBI treatment services to individuals with insurance or alternative sources of 
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care due to budgetary constraints.  In light of these changes, refugees with insurance 
will receive their LTBI care from their primary care providers at a local FQHC.  
Whether this shift in the locus of care will affect patient compliance with LTBI 
evaluation and treatment is not yet known.    
 
Our data show that refugee-status may be an important factor in whether or not a 
foreign-born patient is likely to comply with LTBI screening and treatment.  This 
finding suggests that additional outreach efforts and closer collaboration with patient 
referral sources may be required for non-refugee patients in order to improve rates of 
adherence to LTBI screening and treatment. Additionally, incentive programs, case-
management or social work support, and perhaps more flexibility in appointment 






Figure I. Flow of patients referred to the Baltimore City Health Department for TB 
screening, February 2009-March 2011 (N=1357).  
 
a Among each of the three immigration status groups there was a significant difference in the proportion 
of patients who reported to the BCHD TB Program for a LTBI evaluation (p<0.001). 
b In an overall comparison of the proportion of patients who were diagnosed with LTBI there was no 
significant difference between immigrant groups (p= 0.056). 
c Among each of the three immigration status groups there was a significant difference in the proportion 
of patients who were diagnosed with LTBI that initiated treatment (p<0.001). 
d Treatment completion rates shown here are calculated from among only those patients who initiated 
treatment.  Among each of the three immigration status groups there was a significant difference in the 
proportion of patients who completed treatment (among those who initiated) (p<0.001). Treatment 
completion among all patients who were eligible for treatment (i.e. all patients diagnosed with LTBI) 
were as follows:    81% (296/366) for refugees, 50% (113/229) for non-refugee foreign-born, and 35% 
(86/246) for US-born patients.  The proportions of patients who completed treatment among all those who 




Table I. Description of Patients Referred to and Evaluated by the BCHD TB 
Program for latent tuberculosis infection 

























 Male 280/473 (59%) 186/397 (47%) 311/487 
(64%) 
257/427 (60%) 143/281 (51%) 197/311 
(63%) 
Female 193/473 (41%) 211/397 (53%) 176/487 
(36%) 




31e 32 45 31f 32 47g 
0-14 78/473 (12%) 48/397 (12%) 11/487 
(2%) 
72/427 (17%) 39/281 (14%) 6/311 
(2%) 
15-24 92/473 (20%) 67/397 (17%) 56/487 
(12%) 
85/427 (20%) 41/281 (15%) 32/311 
(10%) 
25-44 212/473 (45%) 195/397 (49%) 179/487 
(37%) 
188/427 (44%) 133/281 (47%) 107/311 
(34%) 
45-64 71/473 (15%) 76/397 (19%) 217/487 
(45%) 
65/427 (15%) 60/281 (21%) 150/311 
(48%) 
>65 20/473 (4%) 11/397 (3%) 8/13 
(62%) 
17/427 (4%) 8/281 (3%) 16/311 
(5%) 
Country of Birth 


































































-- 7/397 (2%) 238/487 
(49%) 









-- 59/397 (15%) -- -- 42/281 (15%) -- 
Immigration -- 53/397 (13%) -- -- 43/281 (15%) -- 
HIV 
programs 
-- 5/397 (1%) 19/487 
(4%) 




-- 60/397 (15%) 58/487 
(12%) 
-- 52/281 (19%) 31/311 
(10%) 
Otheri -- 158/397 (40%) 172/487 
(35%) 
-- 101/281 (36%) 110/311 
(35%) 
e There was a significant difference in median age of patients referred to the BCHD TB program 
among the three immigration-status groups (p<0.001). 
f There was a significant difference in median age of patients evaluated by the BCHD TB program 
among the three immigration-status groups (p<0.001). 
g The median age (43) of US-born patients who did not report to the BCHD TB program for an 
evaluation was significantly lower than those US patients who were evaluated (p=0.030). There was 
no significant difference in median age among patients who were and were not evaluated in the 
other two immigration-status groups.  
h Individuals with evidence of inactive TB infection on chest radiographs at the time of immigration. 
i Other sources refer to those community sources not listed in table who refer patients to the BCHD TB 








Table II. Description of Patients who Initiated and Completed Treatment for 
LTBI According to Immigration Status 
  LTBI Treatment Initiation among those 
Diagnosed with LTBI (n=652 initiated/841 
diagnosed) 
LTBI Treatment Completion among 





























d / 167 
initiated) 
Treatment Regimen  
INH 111/331 
(34%)j 




37/48 (77%) 57/108 
(53%) 




58/166 (35%) 197/220 
(90%) 
76/101 (76%) 29/58 
(50%) 
Gender  














59/85 (69%) 115/132 
(87%) 




30j 30m 47 31o 29 o 46 o 
0-14 66/69 (96%) 31/36 (86%) 2/5 (40%) 61/66 
(92%) 
26/31 (84%) 1/2 (50%) 
15-24 64/67 (96%) 23/30 (77%) 16/25 (64%) 55/64 
(86%) 




65/108 (60%) 60/87 (69%) 126/144 
(88%) 
44/65 (68%) 31/59 
(53%) 
45-64 50/55 (91%) 32/49 (66%) 81/116 (70%) 46/50 
(92%) 
24/31 (77%) 41/81 
(51%) 
>65 9/15 (60%) 1/6 (17%) 8/13 (62%) 8/9 (89%) 1/1 (100%) 4/86 
(50%) 















































































-- 3/5 (60%) 85/127 (67%) -- 2/3 (67%) 44/85 
(53%) 
Refugee -- -- -- -- -- -- 
B-waiver -- 16/23 (70%) -- -- 15/16 (94%) -- 
Latino health 
organization 
-- 20/32 (63%) -- -- 14/20 (70%) -- 
Immigration -- 24/40 (60%) -- -- 19/24 (83%) -- 
HIV 
programs 




-- 32/46 (70%) 13/24 (54%) -- 25/32 (78%) 5/13 
(38%) 
Other* -- 55/81 (68%) 59/84 (70%) -- 36/55 (65%) 32/59 
(54%) 
j Treatment regimen information was only available for 331/333 refugee patients who initiated 
treatment. Since patients have no knowledge of their treatment regimen assignments prior to 
showing up to initiate treatment, we used the total number of patients who initiated treatment to 
calculate the proportion who initiated treatment for each treatment type. 
k Treatment regimen information only available for 149/152 non-refugee foreign-born patients who 
initiated treatment.  
l Treatment regimen information only available for 166/167 US-born patients who initiated treatment.   
m Among patients who initiated LTBI treatment, there was a significant difference in median age 
between among the three immigration-status groups (p<0.000). 
n The median age (38) of non-refugee foreign-born LTBI positive patients who did not initiate 
treatment was significantly higher than the median age among those who of the same immigration-
status who initiated (p=0.001). There was no significant difference in median age among patients 
who did and did not initiate treatment within the other two immigration-status groups. 
o  There was a significant difference in median age of those completing treatment between  the three 
immigration-status groups (p<0.000). Within each immigration subgroup, there was no significant 





Table III. Analysis of Treatment Initiation and Completion among those Diagnosed 
with LTBI at BCHD 
   Initiated LTBI treatment  
(n=652 initiated/841 diagnosed) 
Completed LTBI treatment  
(495 completed/652 initiated) 
 n (%) OR AOR n (%) OR AOR 
Treatment 
Regimen 
















Gender (%)        
 Male  394/505 
(78%) 







0.79 (0.63-1.0;  

































































Status    r   u 
US-born 167/246 
(68%) 






























p The median (39) age of those LTBI patients who did not initiate treatment was significantly higher than 
the median age (34) of patients who did initiate treatment (p=0.020). 
q Overall p-value for age obtained from likelihood ratio test: p= 0.0003 
r Overall p-value for immigration status obtained from likelihood ratio test: p<=0.001 
s The median (40) age of those patients who did not complete treatment after initiation who did not 
initiate treatment was significantly higher than the median age (32) of patients who did initiate 
treatment (p=0.017). 
t Overall p-value for age obtained from likelihood ratio test: p= 0.5216 
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Background: As foreign born individuals represent the majority of tuberculosis (TB) 
cases in the United States, there is an interest in identifying prior to arrival in the U.S., 
individuals who may be at greatest risk TB. United States (US) policies require 
individuals who wish to immigrate to the US to be medically evaluated for tuberculosis 
(TB) by U.S.-designated overseas physicians.  Individuals who have some evidence of 
TB infection, but who are not thought to be contagious, are considered to have a Class B 
medical condition and are recommended to seek follow-up examination upon arrival to 
the US.  Class B immigrants residing in Baltimore, Maryland receive post-immigration 
TB evaluation at the Baltimore City Health Department TB program (BCHD).  We 
sought to characterize post-immigration TB care for Class B immigrants at BCHD, and 
determine the proportion of immigrants with active TB or LTBI in this high-risk 
population.  
Methods: We conducted a retrospective cohort study consisting of a chart review of 
Class B immigrants who reported to BCHD TB program for post-immigration TB 
evaluation from 2010-2012.   
Results: Among the 205 class B immigrants referred to the BCHD TB program during 
2010-2012 for post-arrival screening, we located and evaluated the clinical records of 
153 (75%) patients who reported to BCHD. Of these individuals, 144 (94%) completed 
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BCHD evaluation including medical exam and chest X-ray; 63 (41%) additionally 
received sputum testing for mycobacterial smear and culture and 108 (71%) received a 
test for latent infection with either a TST or interferon-gamma release assay. The 
median time to evaluation after immigration was 75 days (IQR: 55-98).  At post-
immigration BCHD evaluation, 6 individuals were diagnosed with active TB (4%), and 
76 (53%) were diagnosed with latent TB (LTBI). Among the 6 individuals diagnosed 
with active TB, 6 (100%) were smear-negative, 3 (50%) were culture positive and 4 (67%) 
were asymptomatic; all 6 received and completed active TB therapy at BCHD. Among 
the 76 individuals diagnosed with latent TB, 66 (87%) initiated LTBI therapy and 60 
(91%) completed treatment.  
Conclusions: Despite their having thorough pre-departure medical examinations, we 
found a high prevalence of active TB and LTBI among Class B immigrants evaluated by 
the BCHD-TB program. The majority of the active cases did not report any symptoms at 
their pre-departure examination. These findings underscore the need for post-
immigration TB screening for this high risk group despite pre-immigration evaluations, 







Efforts by local health departments to screen recent immigrants for TB are an important 
component of broader TB control goals.  Foreign-born individuals represent a 
significant source of new cases of active tuberculosis reported in the US. In 2012, the 
incidence of TB was 11.5 times greater among foreign-born individuals in the US than it 
was for individuals born in the US. 20  It has been estimated that 4 out of 5 active TB 
cases among the foreign-born is attributable to reactivation of TB that was likely 
acquired prior to arrival in the US.35  
 
Among the foreign born, there is particular interest in identifying prior to immigration 
individuals, who may be at risk for developing tuberculosis.  Persons applying to 
immigrate to the U.S. are required prior to their arrival to be medically evaluated for TB 
by U.S.-designated overseas physicians.  Individuals who are found to have some 
evidence of tuberculosis infection but who are not thought to be contagious are 
designated as Class B immigrants.36 Applicants whose sputa smears and cultures test 
negative for TB, but who have some clinical indication of TB (such as an abnormal chest 
radiograph or TB symptoms) are classified as B1 immigrants.  Individuals who are 
interferon-gamma release assays (IGRA) positive, or have a tuberculin skin test (TST) 
result of ≥ 10mm but no other indication of active disease, are classified as B2. 
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Individuals who are a contact of a known TB case are classified as B3 applicants. All 
Class B immigrants are allowed to enter the country, but are instructed to report to a 
local health department within 30 days of arrival for follow-up screening and, if 
indicated, treatment. 
 
Local programs to screen and treat recent immigrants, like those in Baltimore City, are 
an important component of local TB control goals.37  Immigrants with Class B medical 
conditions are considered to be at high risk for tuberculosis. Therefore, efforts to 
diagnose and treat TB among this high-risk group offer an important opportunity to 
detect imported cases of TB and to prevent additional cases from occurring 
domestically.   
 
In Baltimore City, the annual incidence of reported cases of active TB (3.4 cases per 
100,000 in 2013) exceeds the national average, with a large proportion of active TB cases 
attributable to foreign-born individuals (62% in 2013; BCHD unpublished data). 20,21   
The Baltimore City Health Department (BCHD) Tuberculosis (TB) program provides 
clinical evaluation and care services to Class B immigrants that settled within the city.  
Since 2007, the guidelines for screening Class B immigrants as published by the State of 
Maryland has required that local health departments perform sputum testing for all 
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Class B immigrants who, upon evaluation, were found to have a productive cough.38 In 
2012, BCHD changed its protocol for evaluating Class B immigrants to consider sputum 
testing of all Class B1 immigrants, regardless of whether they had TB symptoms or not.  
 
Though US programs for identifying and flagging for post-arrival screening immigrants 
who may be at high risk for developing tuberculosis, few studies have been published 
describing efforts by local health departments to evaluate and treat newly arrived 
immigrants.39-42  In light of this, we performed a retrospective chart review of Class B 
immigrants referred to BCHD for TB evaluation between 2010-2012 to describe how 
Class B immigrants were screened in practice and analyzed the extent to which testing 
was conducted according to existing protocols.  This study also aimed to evaluate 
whether recent efforts to conduct additional sputa testing on all Class B immigrants 




We conducted a retrospective cohort study consisting of a chart review of Class B 
immigrants who reported to the BCHD TB program for post-immigration TB evaluation 
in 2010-2012.  The study population included all patients who: 1) were classified as a 
category B immigrant during their pre-immigration medical exam; and, 2) reported to 
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BCHD for post-immigration screening during the study period. Class B immigrants 
who were referred to BCHD for post-immigration screening but who did not appear for 
clinical evaluation (and therefore did not have clinical records) were not included.   
 
We reviewed data from the BCHD’s electronic patient database and a state database to 
identify a list of class B immigrants that may have been evaluated by BCHD during the 
study period.  We then searched BCHD’s clinical records to see if charts existed for 
these individuals.  For those charts that we were able to locate, we examined each to 
confirm that the individual met our inclusion criteria.  Once we deemed a chart eligible 
for inclusion, we abstracted the following information: patient demographic 
information (from patients’ immigration forms); pre-immigration screening information 
(including clinical and diagnostic results contained in immigration forms and clinician 
notes from pre-immigration medical examinations); post-immigration TB symptom and 
diagnostic data (from  clinicians’ notes and laboratory test reports); clinical diagnosis 
and treatment data (from BCHD clinicians’ notes). Patients were considered to have had 
a complete medical exam if they received at BCHD a chest xray, a physical exam, and, 
in some cases, the diagnostic testing necessary to result in a diagnosis of active TB, LTBI 
or to rule out current active TB or LTBI. 
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We summarized clinical and demographic factors among individuals included in this 
study.  We examined the association of these factors with patients’ pre-immigration 
screening results, post-immigration diagnosis, treatment initiation, and treatment 
completion. Categorical data were analyzed using Chi square (χ2) and continuous 
variables were analyzed using median tests.  All data were analyzed using STATA 
Version 10.1 (StataCorp, College Station, Texas). 
 
Ethics committees at the Johns Hopkins University School of Medicine (Baltimore, USA) 
and BCHD approved this research. This study received a waiver of informed consent. 
 
Results 
Patient Demographics and Pre-Immigration Screening 
Among the 205 class B immigrants referred to the BCHD TB program during 2010-2012 
for post-arrival screening, we located and evaluated the clinical records of 153 (75%) 
patients who reported to the health department for an evaluation (Figure 1 and Table 1). 
Sixty-four percent (98/153) of immigrants were male and the median age was 33 (IQR: 
15-58). Across all years in the study, most immigrants entered the U.S. from Nepal 
(98/153, 64%), Philippines (19/153, 12%) and Ethiopia (9/153, 6%); however, there was 




The majority of immigrants were classified during pre-immigration medical evaluation 
as category B1 (108/153, 71%) and B2 (43/153, 28%). Among B1 patients, “discrete 
fibrotic scar or linear opacity” and “infiltrate or consolidation” were the most common 
categories on pre-immigration medical questionnaires selected to describe the 
abnormalities found in these patients’ chest xray status. 
 
Twenty-one percent (32/153) of all immigrants had documentation of prior TB disease 
in their pre-immigration screening (Table II). History of TB varied by B waiver category: 
27% (29/108) of B1, 7% (3/43) of B2 and 0% (0/2) of B3 immigrants had a prior TB noted 
in their pre-immigration medical examination paperwork (p=0.005).  
 
For all classes of immigrants, the median time period between entry to country and 
evaluation by BCHD was 75 days (IQR 55-98 days) (Table I).  We found that the median 
time to evaluation of all immigrants varied significantly by year and was highest in 
2011 (93 days: IQR: 69-112 days; p<0.001). Similarly, the median time that elapsed 
between immigrants’ pre-immigration chest xrays and when they presented to BCHD 
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for evaluation was 201 days (IQR 169-241) and was also longest in 2011 (224 days; IQR 
196-258; p<0.001). 
 
Post-Immigration Evaluation  
All 153 immigrants that reported to BCHD received chest xrays at the TB clinic. 
Abnormalities were found in 43% of all immigrants’ xrays (Table II).  The highest 
percentage of abnormalities occurred among Class B1 immigrants; 57% (62/108) of B1 
immigrants were found to have abnormal post-immigration chest xrays, as compared to 
7% (3/43) of B2 and 0% (0/2) of B3 immigrants (p<0.001). 
 
BCHD performed QFT-GIT testing on 59% (90/153) of immigrants, among whom 53% 
(48/90) tested positive.  Additionally, post-immigration tuberculin skin test (TST) test 
results were available for 29% (43/153) of all immigrants who reported to BCHD for an 
evaluation.  91% (39/43) of all those with post-immigration TST results had indurations 
of ≥10mm. Twenty four immigrants (16%) had both post-immigration TST and QTB 
results available. For these individuals, 18 were QTB positive and had TST indurations 
≥10mm; 5 were QTB negative and had TST ≥10mm, and 1 was QTB negative and had a 
TST result of <10mm. QTB testing differed between B1, B2 and B3 immigrants, with 
most tests occurring among B1s (p<0.001). 
57 
 
Overall, 41% (63/153) of immigrants evaluated by BCHD received both sputa smear and 
culture testing (Table II).  Sputa testing was significantly (p<0.001) more likely to occur 
among B1 immigrants, with 71% (60/108) receiving sputa testing, as compared to B2 
(3/43; 28%) and B3 (0/2; 0%). Sputa testing also differed between patients who reported 
symptoms versus asymptomatic patients. 85% (17/20) of all symptomatic patients 
received sputa testing as compared with 34% of asymptomatic patients (p<0.001). The 
proportion of asymptomatic patients who received sputa testing at BCHD also varied 
with time. Sputa testing of asymptomatic patients was highest in 2012 (16 out of 39 
asymptomatic patients tested; 40%).  This proportion was marginally significantly 
higher than that in 2010, when 9 out of 30 (30%) asymptomatic patients were tested 
(p=0.055).  
 
Post-Immigration Diagnosis  
Overall, 94% (144/153) of the Class B immigrants screened by the health department 
received complete medical evaluations (chest xray and physical exam) that resulted in a 
diagnosis of either current active TB or LTBI or a rule out of both of those conditions 
(Figure 1).  There were 6 cases of active TB among the 144 (4%) immigrants who 
received a complete post-immigration medical evaluation (Table III).  Half of the active 
TB cases (3/6) were refugees from Nepal, the remainder from Eritrea/Ethiopia (2/6, 33%) 
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and Iraq [via Turkey] (1/6, 17%). Eighty-three percent (5/6) of active TB cases were male. 
Among these 6 active TB cases, 4 (67%) were asymptomatic at time of evaluation but 
received further evaluation based on their radiographic features or clinical exam.  Two 
of the 4 asymptomatic patients were found to be sputum culture positive, while two 
were diagnosed clinically based on medical history, exam and xray findings. Among 
the 2 active TB cases that reported symptoms, 1 was culture positive and one was 
diagnosed clinically. All newly diagnosed active TB cases completed treatment. 
 
Fifty-three percent (76/144) of Class B immigrants received a diagnosis of latent 
tuberculosis infection.   Thirty-eight patients (50%) were diagnosed with LTBI on the 
basis of a positive QTB, while 3 (4%) were diagnosed with LTBI based on a positive 
post-immigration TST.  Thirty-five immigrants (46%) were diagnosed and treated for 
LTBI despite a lack of positive post-immigration TST or QTB on the basis of a pre-
immigration TST result or post-immigration chest x ray finding indicative of inactive TB 
infection.  The vast majority of these patients (50/76, 66%) emigrated from Nepal. 
Eighty-two percent of LTBI patients were <15 years of age and 68% were male.  Among 
those diagnosed with LTBI, 87% (66/76) initiated LTBI therapy, with 91% (60/66) 
completing treatment. Treatment completion among all those diagnosed with LTBI who 
were eligible for treatment was 79% (60/76). 
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Overall, 43% (62/144) of those who completed post-immigration evaluation were found 
to have no evidence of current active TB or LTBI and were not recommended to 
complete any further TB treatment.  Among these 62 individuals, 40% (25/62) had 
documentation in their immigration paperwork of prior treatment for tuberculosis, 
while the remainder (37/62, 60%)  had active TB or LTBI excluded on the basis of a 
combination of QGIT testing (negative QGIT in 32/37, 86%), post-immigration chest 
xray (no evidence of active or inactive TB in 31/62, 50%), and/or sputum evaluation 
(negative mycobacterial culture in 100% of the 28/62 (45%) of immigrants tested).   
 
We examined differences among those who reported symptoms at time of examination 
versus those who did not.  Of the 144 patients who received a complete medical 
examination, only 20 (14%) patients reported having any symptoms at the time of their 
examination.  Active TB, LTBI and no current TB disease or infection were diagnosed in 
10% (2/20), 45% (9/20) and 45% (9/20) of symptomatic patients, respectively (p= 0.336).  
Among the asymptomatic patients, 3% (4/124) were diagnosed with active TB, 54% 





Despite their having thorough pre-departure medical examinations, we found a high 
period prevalence of active TB (4%) and LTBI (53%) among Class B immigrants 
evaluated by the BCHD-TB program.  Of the approximately  40 percent of Class B 
immigrants who were found to have neither current active TB nor LTBI, half did not 
have abnormalities on their post-immigration chest xray and 40% percent had evidence 
in their immigration paperwork of having prior treatment for TB.   
 
These findings highlight the difficulties associated with TB diagnostics.  Recent (2009) 
guidance by the CDC has intensified the pre-immigration screening procedures.6  Class 
B immigrants arriving in Baltimore during the study period had substantial pre-
immigration evaluations, including pre-immigration sputum mycobacterial cultures 
performed for all those with abnormal chest x-rays (Class B1).  Our data suggests that 
serial testing and evaluation of high-risk individuals, both before and after 
immigration, is a necessary component to enhanced TB case-finding strategies.    
Among the challenges to TB screening and case-finding is the ability to identify sub-
clinical or pauci-bacillary disease.  Many TB screening algorithms rely upon presence of 
symptoms to initiate further microbiologic testing or further imaging evaluations.  
However, our study found that in this high-risk population, two-thirds of the identified 
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active TB cases reported no symptoms; overall, half of these active TB cases were 
diagnosed by sputum culture, while the remainder were clinically diagnosed based on 
imaging, symptoms, and other clinical findings following extensive evaluations.  These 
results offer important insights for policy related to post-immigration examinations for 
Class B1 immigrants.  Given the high proportion of asymptomatic active TB disease 
identified, clinicians should strongly consider evaluating sputa for AFB smear and 
mycobacterial culture, along with other directed testing, from high-risk patients with 
abnormal chest xrays, regardless of pre-immigration microbiologic testing.  
 
Nearly all immigrants diagnosed with either LTBI or active TB completed treatment for 
their illness. Though these adherence rates observed in this analysis are similar to those 
in our previous analysis, they are higher than typically reported in the literature.[CITE] 
High-rates of treatment suggests that local examination and treatment of patients can be 
effective in reducing the overall burden of TB in the community. 
Despite these successes, there remain challenges to local screening efforts. An important 
issue is the length of time between immigrants’ entry to the US and post-immigration 
evaluation. Nationally, it has been reported that the median time from arrival to post-
immigration evaluation for class B immigrants is 39 days43.  However, at BCHD, we 
found that the median time to evaluation was 75 days and was longer than these 
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national survey data, and evaluation was significantly more delayed than CDC’s 
recommendation of 30 days.  It should also be noted that there are additional delays 
generated between the time of pre-immigration clinical evaluation and a patient’s 
arrival in the US.  In our study, we found greater than 4 months had elapsed between 
the time of pre- and post-immigration evaluations; in some cases, greater than 1 year 
had elapsed.  While our study did not directly evaluate reasons for these delays, they 
are likely multi-factorial and include patient factors as well as health system factors.  
Individuals, particularly refugees, immigrating to the US may have competing medical 
appointments and responsibilities which preclude timely participation in health 
department directed TB evaluations.  Resources and staffing at local health 
departments, including BCHD, are also increasingly becoming limited which may 
contributed to appointment delays.  For example, the median number of days from 
immigrant entry to BCHD evaluation was highest in 2011; these delays were coincident 
with a time period when BCHD experienced its highest volume of both active TB and 
latent TB patients, and had limited staffing. Additional prospective studies are needed 
to more specifically determine where in the post-immigration time period delays in 




In light of this, time to evaluation should be considered when defining protocols for 
domestic screening of Class B immigrants post-arrival.  Clinicians may want to consider 
ordering repeat sputa and other diagnostic tests for immigrants for whom significant 
time has elapsed since their pre-immigration medical examination.  Screening protocols 
for Class B immigrants should also factor in time to evaluation when defining whether 
to re-test patients upon arrival, regardless of patients’ current symptoms.  
 
There were some limitations to our study.  First, Class B immigrants in Baltimore were 
largely comprised of refugees from a few specific settings.  The high prevalence of 
active TB in this group, may reflect risk factors specific to the study population that are 
not generalizable to individuals emigrating from other settings/regions.  Secondly, our 
overall sample size was small which can impact point estimates and may be subject to 
temporal trends.  Nonetheless we are among the first in recent years to report on details 
of post-immigration TB screening practices at a representative urban local health 
department across a three year time period, and our period prevalence estimates are 
consistent with other published data from the state and national level39,42 37. Finally, our 
study was largely retrospective and long-term follow-up data on class B immigrants 
was not available; future studies to evaluate incidence of active TB among class B 
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immigrants over time are warranted to help guide policy regarding further TB 
screening in this high risk group.   
 
The prevalence of active TB and LTBI observed among Class B immigrants in this study 
underscore the importance of post-arrival evaluation of this high risk group.  Diagnosis 
is complicated by the absence of symptoms in a majority of active TB cases and long 
delays between immigrants’ entry to the US and post-immigration evaluation. Despite 
these challenges, high rates of treatment achieved by BCHD suggest local programs to 
screen and treat recent immigrants can be effective in reducing the burden of TB within 












Figure I. Flow of Class B Immigrants Screened by Baltimore City Health Department 















Table I. Description of All B Waiver Patients Seen by the BCHD TB Program 
for Tuberculosis, by Year (2010-2012) 
  Evaluated by BCHD TB Program (N=153) 
  2010 (n=36) 2011 (n=67) 2012 (n=50) TOTAL 
(N=153) 
Gender (%) (p=0.291)     
 Female 9/36 (25%) 26/67 (39%) 20/50 (40%) 55/153 (34%) 
 Male 27/36 (75%) 41/67 (61%) 30/50 (60%) 98/153 (64%) 
Age (median (IQR)) 
(p=0.033) 
30 (15-51) 42 (23-67) 29 (14-47) 33 (14-58) 
 0-14 9/36 (25%) 16/67 (24%) 14/50 (28%) 39/153 (26%) 
 15-24 6/36 (17%) 3/67 (5%) 7/50 (14%) 16/153 (10%) 
 25-44 10/36 (28%) 15/67 (22%) 14/50 (28%) 39/153 (26%) 
 45-64 7/36 (19%) 14/67 (21%) 10/50 (20%) 31/153 (20%) 
 >65 4/36 (11%) 19/67 (28%) 5/50 (10%) 28/153 (18%) 
Country of Origin/Origination     
Other 9/36 (25%) 4/67 (6%) 5/50 (10%) 18/153 (12%) 
Bhutan/Nepal 17/36 (47%) 49/67 (73%) 32/50 (64%) 98/153 (64%) 
Philippines 6/36 (17%) 6/67 (9%) 7/50 (14%) 19/153 (12%) 
Eritrea/Ethiopia 3/36 (8%) 6/67 (9%) 0/50 (0%) 9/153 (6%) 
Dominican Republic 1/36 (3%) 1/67 (2%) 3/50 (6%) 5/153 (3%) 
Iraq/Turkey 0/36 (0%) 1/67 (1%) 3/50 (6%) 4/153 (3%) 
B Waiver Category 
(p=0.893) 
    
 B1  25/36 (69%) 49/67 (73%) 34/50 (68%) 108/153 (71%) 
 B2 11/36 (31%) 17/67 (44%) 15/50 (33%) 43/153 (28%) 
 B3 0/36 (0%) 1/67 (1%) 1/50 (2%) 2/153 (1%) 
Abnormalities Reported in Pre-
Immigration Chest X-ray (B1 
immigrants only) 
    
Infiltrate or consolidation 13/25 (52%) 19/49 (39%) 18/34 (53%) 50/108 (46%) 
Any cavitary lesion 2/25 (8%) 3/49 (6%) 2/34 (6%) 7/108 (7%) 
Nodule with poorly defined 
margins 
1/25 (4%) 4/49 (4%) 2/34 (6%) 5/108 (5%) 
Pleural effusion 0/25 (0%) 0/49 (0%) 1/34 (3%) 1/108 (1%) 
Hilar mediastinal adenopathy 0/25 (0%) 1/49 (2%) 0/34 (0%) 1/108 (1%) 
Linear interstitial markings 1/25 (4%) 0/49 (0%) 1/34 (3%) 2/108 (2%) 
Discrete fibrotic scar or linear 
opacity 
11/25 (44%) 35/49 (71%) 23/34 (68%) 69/108 (64%) 
Discrete nodule without 
calcification 
1/25 (4%) 2/49 (4%) 1/34 (3%) 4/108 (4%) 
Discrete fibrotic scar with 
volume loss or retraction 
2/25 (8%) 4/39 (4%) 3/34 (9%) 9/108 (8%) 
Other 5/25 (20%) 15/39 (31%) 9/34 (27%) 29/108 (27%) 
History of prior TB (noted in 6/36 (17%) 15/67 (22%) 11/50 (22%) 32/153 (21%) 
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immigration paperwork)  
(p=0.624) 
Median Days from Entry to 
Evaluation by Health 
Department (range) (p<0.001) 
62 (53-77) 93 (69-112) 61 (45-80) 75 (55-98) 
Median Days Since Last Pre-




















Table II. Summary of Post-Immigration Examination of All Immigrants for 
Tuberculosis, By Classification* 
  Post-Immigration Screening Results for Immigrants 
Evaluated by BCHD TB Program 
  B1 (n=108) B2 (n=43) B3 (n=2) All Classes 
(N=153) 
History of prior TB (noted in pre-
immigration medical examination 
paperwork)  
(p=0.005) 
29/108 (27%) 3/43 (7%) 0/2 (0%) 32/153 (21%) 
Any symptoms at time of evaluation  
(p=0.034) 
19/108 (18%) 1/43 (2%) 0/2 (0%) 20/153 (13%) 
Post-immigration HIV test 
conducted (p<0.001) 
70/108 (65%) 14/43 (33%) 0/2 (0%) 84/153 (55%) 
HIV test positive (p=0.001) 0/0 (0%) 2/14 (17%) 0/2 (0%) 2/84 (2%) 
Post-immigration  TST results 
available 
33/108 (31%) 10/43 (23%) 0/2 (0%) 43/153 (29%) 
TST Positive (≥10mm) 
 
29/33 (89%) 10/10 (24%) -- 39/43 (91%) 
Received Quantiferon Testing 
(p<0.001) 
78/108 (72%) 12/43 (28%) 0/2 (0%) 90/153 (59%) 
 Positive   42/78 (72%) 0/12 (0%) 0/2 (0%) 48/90 (53%) 
Abnormal Post-Immigration Chest 
Xray (p<0.001) 
62/108 (57%) 3/43 (7%) 0/2 (0%) 65/153 (43%) 
Received Sputa Testing ⱡ (p<0.001) 60/108 (71%) 3/43 (28%) 0/2 (0%) 63/153 (41%) 
Smear Positive  
 
0/60 (0%) 0/43 (0%) 0/0 (0%) 0/63 (0%) 
Culture Positive  
 
3/60 (5%) 0/43 (0%) 0/2 (0%) 3/61 (5%) 
Completed Medical Evaluation 
(p=0.136)  
99/108 (92%) 43/43 (100%) 2/2 (100%) 144/153 (945) 
Active TB (p= 0.724) 5/99 (5%) 1/43 (2%) 0/2 (0%) 6/144 (4%) 
LTBI (p<0.001) 39/99 (39%) 35/43 (81%) 2/2 (100%) 76/144 (53%) 
No current LTBI/TB disease (p<0.001) 55/99 (56%) 7/43 (16%) 0/2 (0%) 62/144 (43%) 
* P values presented in this table represent comparison between b waiver categories for each variable. 
ⱡ Sputum testing includes acid-fast bacilli (AFB) smear microscopy and mycobacterial liquid culture. Patients received sputum 









Table III: Characteristics of B Waiver Patients who Received Full Clinical 
Evaluations, by Diagnosis Category (Active TB, LTBI or No TB Infection)* 




No TB Infection of Disease 
(n=62) 
Gender     
 Female 1/6 (17%) 24/76 (32%) 26/62 (42%) 
 Male 5/6 (83%) 52/76 (68%) 36/62 (58%) 
Age (median (IQR)) (p=0.021) 29 (14-30) 23 (12-49) 41 (27-59) 
Country of Origin/Origination    
Other 0/6 (0%) 7/76 (9%) 10/62 (16%) 
Bhutan/Nepal 3/6 (50%) 50/76 (66%) 38/62 (61%) 
Philippines 0/6 (0%) 8/76 (11%) 11/62 (18%) 
Eritrea/Ethiopia 2/6 (33%) 6/76 (8%) 1/62 (2%) 
Dominican Republic 0/6 (0%) 2/76 (4%) 2/62 (3%) 
Iraq/Turkey 1/6 (17%) 3/76 (4%) 0/62 (0%) 
History of prior TB (noted in pre-
immigration paperwork) (p<0.001) 
1/6 (17%) 4/76 (5%) 25/62 (40%) 
Median days from entry to 
country to evaluation (IQR)  
105 (63-125) 74 (53-98) 76 (57-98) 
 
Abnormal Pre-Immigration 
Chest Xray (p<0.001) 
5/6 (83%) 40/76 (53%) 55/62 (89%) 
Infiltrate or consolidation 2/5 (40%) 5/40 (13%) 9/55 (16%) 
Any cavitary lesion 0/5 (0%) 0/40 (0%) 2/55 (4%) 
Nodule with poorly defined 
margins 
0/5 (0%) 0/40 (0%) 2/55 (4%) 
Pleural effusion 0/5 (0%) 0/40 (0%) 0/55 (0%) 
Hilar mediastinal adenopathy 0/5 (0%) 1/40 (3%) 0/55 (0%) 
Linear interstitial markings 0/5 (0%) 0/40 (0%) 0/55 (0%) 
Discrete fibrotic scar or linear 
opacity 
1/5 (20%) 24/40 (60%) 27/55 (49%) 
Discrete nodule without 
calcification 
1/5 (20%) 3/40 (8%) 1/55 (2%) 
Discrete fibrotic scar with volume 
loss or retraction 
1/5 (20%) 4/40 (10%) 3/55 (6%) 
Other 0/5 (0%) 3/40 (8%) 11/55 (20%) 
Abnormal Post-Immigration 
Chest Xray (p<0.001) 
5/6 (83%) 23/75 (31%) 31/62 (50%) 
 
Reported Symptoms  2/6 (33%) 9/76 (12%) 9/62 (15%)  
Received Sputa Testing 2/2 (100%) 8/9 (89%) 7/9 (78%) 
Culture Positive 1/2 (50%) 0/8 (0%) 0/7 (0%) 
Did Not Report Symptomsⱡ  4/6 (67%) 67/76 (88%) 53/62 (86%) 
Received Sputa Testing 4/4 (100%) 17/67 (25%) 21/53 (43%) 
Culture Positive 2/4 (50%) 0/17 (0%) 0/21 (0%) (p<0.001) 
Completed Treatment 6/6 (100%) 60/66 (91%) -- 
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Though the total number of TB cases reported in the US is decreasing, persistently high 
incidence among foreign-born individuals have slowed progress towards national TB 
elimination.  Driving down incidence in the foreign born will require going after the 
pool of latently infected individuals who represent an important source of future TB 
cases.  In light of this, expert groups have called for targeted testing and treatment of 
LTBI of high-risk individuals, such as the foreign-born, to further US TB elimination 
goals. However, public health departments, which conduct the majority of LTBI testing 
and treatment in the United States, have largely not been able to maintain dedicated 
programs for targeted testing and treatment of foreign-born individuals.  In this article, 
we review the importance of LTBI testing and treatment of the foreign-born, and 
discuss ways to equip health departments to complete this important pillar of the US 








For the last 20 years, the United States has seen a steady decrease in the annual number 
of TB cases.  In 2013, fewer than 10,000 new TB cases were reported across the 
country—the lowest number of incident cases since reporting began in the 1950s.   
Despite this welcome progress, the percent reduction in new TB cases has slowed in 
recent years and the current incidence of TB cases in the U.S. (3.0 per 100,000 
population) still exceeds CDC's TB elimination goal of having <1 case per 1 million 
population.1 The CDC has estimated that at the rate the TB incidence has been declining 
in recent years, TB elimination may not be possible until the year 2107.2  
 
One of the biggest obstacles to eliminating TB from the United States is persistently 
high incidence of TB among the foreign-born.  The majority of U.S. TB cases now occur 
among the foreign-born and efforts to reduce incidence in this group have been slow 
compared to U.S. born. Since 1993, the annual incidence of TB among U.S.-born 
individuals has decreased by more than 80%., from 7.4 cases per 100,000 to 1.4 per 
100,000.  But incidence among the foreign-born has been consistently higher—falling 




Driving down incidence in the foreign born will require going after the pool of latently 
infected individuals who represent an important source of future TB cases.  Studies 
suggest that a major contributor to TB cases in the US is the reactivation of infections 
acquired abroad. Eighty percent of active TB cases reported in the U.S. have been 
attributed to reactivation of prior infection, rather than newly transmitted infection.3 
The rate of reactivation TB among persons with latent TB infection (LTBI) is higher 
among foreign-born persons than among persons born in the United States.  It has also 
been shown that the risk of reactivation persists long after arrival in the United States, 
even though LTBI screening guidelines suggest targeting only those individuals who 
have been in the country for fewer than 5 years.4   
 
Though targeted testing and treatment of LTBI in high-risk individuals, such as the 
foreign-born, has been recognized by the Institute of Medicine and the US Centers for 
Disease Control and Prevention as a necessary to achieve U.S. TB elimination goals, it 
remains an overlooked component of TB control efforts in the US.  US policies do not 
require pre-arrival LTBI screening for adult immigrants and foreign-born visitors to the 
United States.  Program objectives and performance targets developed by the CDC to 
evaluate TB control programs in the US contain no metrics for LTBI screening and care.5  
State and local public health departments, which conduct the vast majority of all LTBI 
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treatment in the United States, have not been able to maintain dedicated programs to 
test and treat those at greatest risk for LTBI, such as foreign-born individuals.6,7   
Competing priorities, insufficient funding and other operational obstacles have 
hindered progress on this front to-date.  In this article, we review the importance of 
LTBI testing and treatment of high risk individuals, such as the foreign-born, and 
discuss ways to equip health departments to complete this important pillar of the US 
strategy for TB elimination. 
 
Current Challenges 
Declining Funds for TB Control Activities 
Though fewer confirmed TB cases have been reported each year, the demands placed 
on public health departments for TB control activities have remained high. Health 
departments expend significant effort in managing individuals in whom TB will 
eventually be ruled out, which is not reflected in annual incidence numbers. The clinical 
heterogeneity of TB makes its disease presentation difficult to distinguish from several 
other conditions. As a result, public health departments must be equipped to offer 
broad diagnostic services, yet only a small proportion of individuals referred for care 
will ultimately receive a final diagnosis of active TB.8 For every case of infectious TB 
diagnosed, public health agencies must also identify people who may have had contact 
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with the infected individual—on average, 10 contacts per case.9,10 Public health agencies 
must locate, interview and evaluate each of these contacts.  In total, the number of tests 
performed can far exceed the number of confirmed cases of active TB.  A study 
conducted in Texas, found that for each case of TB that was confirmed in 2002, 148 
cultures were performed on contacts within the community.11  
 
Costs associated with providing public health related TB services continue to increase.  
While the emerging diagnostic tests for TB and LTBI have provided new opportunities 
for diagnosing infection and active disease, the adoption of new tests places additional 
demands on public health infrastructure.  For example, the CDC now requires that in 
addition to performing sputa culture, health departments should also perform nucleic 
acid amplification testing (NAAT) on the sputa from all individuals who are considered 
to be TB suspects.12   A recent cost-effectiveness analysis suggested that testing of at 
least one sputum sample with Xpert MTB/Rif (an FDA- and WHO- endorsed NAAT) 
would increase laboratory costs by over 60% per patient13.  These increased costs 
associated with improved or new technology place added stress on under-funded 
health departments.  
 
The emergence of drug resistant tuberculosis has also placed severe demands on public 
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health departments tasked with their management. The average costs of treating a 
single case of MDR and XDR TB, is $131,000 and $430,000, respectively.14 Since MDR 
and XDR cases typically occur among indigent patients, public agencies typically bear 
the burden of treatment costs. The high costs of treating drug-resistant will likely 
continue, even as new drugs enter the market for the first time in several decades. 
Bedaquiline, which was recently approved by the FDA for the treatment of MDR-TB, 
will likely cost the public sector $23,000 for a single treatment course.15   
 
Despite persisting demands on public health departments for TB control, there has been 
decreasing support from federal government via cooperative agreements.  For the last 
10 years, federal funding for state/local TB control activities has remained constant, 
which, factoring in inflation, has meant that that the amount of resources available for 
tuberculosis control have declined substantially (see Figure 1).  At the same time, the 
risk that TB will be imported to the United States persists, as number of legal 
immigrants (i.e. legal permanent residents, refugees, asylees, parolees), non-immigrant 
visitors and unauthorized immigrants that enter the US each year has remained stable 




Combined with state budget cuts following the recent recession, declining federal 
support for TB control has forced health departments to make tough choices.  A survey 
conducted by the National Tuberculosis Controllers Association (NTCA) found that 
sixty percent of TB control programs have had to eliminate staff as a result of shrinking 
budgets.17  Twenty-five percent of programs reported having to restrict some essential 
TB activities, such as provision of directly observed therapy, contact and outbreak 
investigations.  
 
The absence of dedicated funding specific for LTBI treatment and evaluation is a further 
disincentive for health departments to give priority to such activities.  Though LTBI 
treatment and evaluation was once a part of national TB control efforts, budget cuts 
have forced CDC to focus its efforts on control of active TB cases. 18  Since 2005, there 
has been no explicit federal funding for LTBI treatment and evaluation and, as a result, 
many health departments have been able to only offer limited LTBI screening and 
treatment.19 
 
Absent a significant increase in the amount of federal funds allocated to state and local 
health departments for tuberculosis control activities, the lack of prioritization of LTBI 
testing and treatment is likely to continue for some time.  In 2008, the CDC’s Division of 
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Tuberculosis Elimination in conjunction with the National Tuberculosis Controllers 
Association began a process to develop new formula to guide allocation of increasingly 
diminished TB control funding.  The new funding scheme, which is to be phased in 
over the next several years, eliminates base funding to all jurisdictions, in favor of 
incidence-based funding.20 Though new the funding formula does contain provisions 
related to targeted testing and treatment of LTBI, such as the population of foreign-born 
and high-risk immigrants residing in a location—it does not specifically address LTBI 
testing and treatment.21  
 
Low Adherence to LTBI Treatment 
 Reviews of initiatives to screen and treat foreign-born individuals have found that 
effectiveness of these efforts is often compromised by low compliance among patients.  
A recent systematic review found uptake in all steps of screening and treatment process 
was suboptimal: frequently, patients fail to complete screening and those that do and 
are diagnosed with LTBI often do not initiate treatment.19,22 When patients do initiate 
treatment for LTBI, completion is generally low.    Numerous studies have tried to 
identify predictors of poor treatment compliance.  The results of these analyses have 
been varied, which suggests that there are many potential factors that contribute to poor 
adherence.23    Many of the factors identified in these studies—e.g., age, gender, 
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employment status, marital support—are difficult to address in the context of 
traditional models for providing clinical care, which complicates efforts to reduce LTBI. 
 
Innovative approaches are needed to ensure effectiveness of LTBI treatment programs 
is not marred by poor patient compliance.  For example, some programs have employed 
case management models for administering treatment of LTBI have reported increased 
compliance with LTBI treatment among high-risk patients such as refugees and 
homeless individuals. 24-26 At least one study is examining whether employing new 
technologies, such as mobile phone text messages, may also boost patient adherence.27  
 
High Cost of New Regimens 
Though new, shorter regimens have been developed to reduce the burden of 
compliance with LTBI treatment, the high cost associated with these regimens can place 
them out of reach for many health departments.  The CDC has recommended that a 
combination of INH and rifapentine delivered over three months with directly observed 
therapy (DOT) is as effective and is associated with greater patient compliance than a 9 
month course of INH without DOT.28  However, the per-patient cost of this new 
regimen has been reported to be more than 10 times greater than administering 9 
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months of INH.29 Moreover, the requirement that DOT be used to administer the 
regimen also increases the resources drain on health departments. 
 
Lack of Stable Supply Chains for LTBI Testing and Treatment Supplies  
Recently, TB control efforts have been slowed by widespread shortages of critical TB 
medicines and testing supplies.  In 2013, the two US-approved manufacturers of 
tuberculin, the active ingredient used in the Tuberculin Skin Test (TST), reported 
having insufficient supplies to meet demand.30,31   A survey conducted by the CDC 
found that the difficulty in obtaining tuberculin has had a considerable impact on 
health departments; fifty-six percent of those surveyed by CDC reported that routine TB 
control activities were being threatened or curtailed by the shortages.32  At the time of 
this writing, tuberculin is still in short supply.33 
 
The CDC recommended that health departments and clinicians respond to tuberculin 
shortages by reserving TST testing for those at greatest risk (e.g. TB contact 
investigations) and substituting IGRA testing where possible. Though many health 
departments and clinics have already begun using IGRA tests, TST remains an 
important tool in both outbreak investigations and LTBI screening.  First, IGRA testing 
requires sufficient laboratory infrastructure and material costs of IGRA testing is more 
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expensive on a per test basis than TST.34  Both of these traits can make it difficult to 
switch to or rely more heavily on IGRA testing without additional resources and 
planning. Second, TST is still routinely used as the preferred means of testing for TB 
infection in certain patient groups, such as young children. 
 
Control of LTBI has been further complicated by recent shortages in isoniazid (INH)—a 
critical medicine used to treat both TB infection and active diseases.35 The shortages, 
which began suddenly in November 2012, persisted well into 2013 and beyond. A 
survey of health departments by the CDC determined that 79% of respondents 
experienced difficulties in procuring INH. Among those experiencing shortages, 68% 
reported that they were delaying LTBI treatment as a result.  
 
Future Challenges  
Changes Associated with the Affordable Care Act 
Another question that needs to be answered by public health: What will be the impact 
of Affordable Care Act (ACA) on efforts to increase targeted testing and treatment of 
LTBI among high risk individuals? As previously uninsured individuals people gain 
coverage under the ACA, care of some patients who previously sought treatment at 
86 
 
public clinics will likely shift to the private sector.  These changes, along with continued 
budget cuts and staff losses at public clinics, may change public health’s role in being 
able to provide clinical services like LTBI diagnosis and treatment.   
 
This raises questions about private clinicians’ abilities and willingness to offer LTBI 
screening and treatment. Typically, adherence in private clinics to national 
recommendations for targeted testing and treatment of high risk individuals for LTBI 
has been low. 36  Studies have also demonstrated that clinicians outside of the public 
sector may have low levels of knowledge about and interest in screening patients for 
LTBI.18   
 
For private sector clinicians to assume a greater role in LTBI screening and care, it will 
likely require additional training regarding the diagnosis of LTBI, treatment regimens.  
Moreover, since treatment for LTBI is lengthy, the private sector may have to develop 
plans to provide longitudinal tracking of patients to determine who completes 
treatment, who experiences adverse outcomes, etc.37 Moreover, it may not be possible to 
offer new LTBI therapies that require DOT, unless private clinicians develop a way for 




There are also questions regarding the extent to which LTBI screening and treatment 
costs will be covered under the ACA’s new model of care.  For example, costs 
associated with LTBI screening and treatment may not be covered as a non-cost shared 
preventative service—that is, without passing along some of the costs to the insured 
patient.38  Compliance with LTBI screening and treatment may be reduced if patients 
are required by their health plans to shoulder some of the costs.  
 
 
Even with expanded coverage under the ACA, significant numbers of the population 
that will remain uninsured because they don’t qualify for coverage.  Many of these 
patient groups (e.g., undocumented immigrants) are among those who should be 
targeted for LTBI screening and care. States will have to plan for how to deliver LTBI 
screening and treatment to those uninsured individuals. 
 
 
Some public health departments have begun to explore billing for the clinical services 
that they provide.  Though this seems like a promising option for public health 
jurisdictions that would like to retain oversight and control over LTBI screening and 
treatment, difficulties in establishing billing procedures and legal restrictions have 
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proven to be important obstacles in doing so. In Baltimore City, efforts to in-house 
efforts bill for clinical services have only resulted in 10% of claims being reimbursed.39  
 
Measuring Progress 
In an era of competing public health priorities and dwindling resources, it is important 
to measure impact of disease control activities.  As TB incidence continues to decline 
and the work of TB control shifts to LTBI screening and treatment, a fundamental 
question remains:  how will we measure the impact of LTBI testing and treatment?  
LTBI is not a reportable condition, so it will be difficult to measure the number of 
individuals diagnosed with LTBI via traditional means of surveillance.  Declines in 
reported active TB is one potential way to  measure of community-wide efforts to 
reduce the pool of LTBI, but it does not directly capture the work that goes into finding 
and treating LTBI. Ideally, efforts to conduct targeted screening and treatment would be 
supported by a surveillance system that enumerates the proportion of LTBI-infected 
individuals who are diagnosed with LTBI and those who initiate and, ultimately 
complete treatment.   
 
Conducting surveillance for LTBI and measuring progress towards its elimination will 
be made more difficult if the locus of LTBI screening and treatment shifts from public 
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health departments to the private sector. Because LTBI is not a reportable condition, it 
will be difficult for public health to gauge what proportion of infected individuals are 
being identified and treated outside of public health clinics.  
 
It is possible that the increasing adoption of electronic medical records that is occurring 
across the country may help with surveillance of LTBI.40  This will require there be a 
way to structure or query records to determine who tests positive on TST or IGRA.  
Additional work will also be needed to track patients to determine who initiates and 
completes treatment.   
 
Refining Targets 
Analyses suggest that efforts to screen and treat LTBI are most cost-effective when they 
focus on high-risk individuals, such as the foreign-born.  However, in the absence of a 
significant increase in the amount of resources to support expanded LTBI screening and 
treatment programs, demographic realities suggest that even targeted testing may not 
be cost-feasible.  In 2012, there were close to 41 million foreign-born individuals living 
in the United States.41 Over the last 30 years, the percentage of the U.S. population that 
was born abroad has steadily increased and, absent any major shift in national 
immigration policy, this trend is likely to persist.  What this means is that the number of 
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potential “targets” for targeted LTBI screening will continue to grow and outpace 
resources available for screening initiatives. 
 
It would be beneficial to be able to better define who is truly at risk for progressing to 
disease once infected.  On average, 90% of individuals who become infected with 
tuberculosis will never develop active TB.  Additional studies aimed at addressing this 
question may help improve efforts towards TB elimination. 
 
Conclusions 
If there is to be meaningful progress towards eliminating TB from the United States, the 
nation must make a dedicated effort to down TB incidence by reducing incidence of TB 
among the foreign-born.  Limited progress in controlling TB in this group and evidence 
that the majority of TB cases that arise among the foreign-born is attributed to 
reactivation of infection likely acquired abroad, strongly support the need for expanded 
testing and treatment of LTBI of the foreign-born. 
Historical trends and documented gaps in knowledge in the private sector indicate that 
public health departments will for some time have to play a lead role in efforts to 
reduce LTBI among the foreign-born. However, a lack of sufficient, dedicated funding, 
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unstable supply chains, and low patient compliance have made it difficult for health 
departments to give priority within their TB control programs to efforts to conduct 
targeted testing and treatment for LTBI.  In addition, future questions about how the 
ACA and changing demographics will affect the distribution, surveillance and 
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CHAPTER 5: CONCLUSIONS 
 
 
Despite recent successes in reducing the total number of active TB cases reported each 
year, the US remains far from achieving its TB elimination goal of <1 case per million 
population. Meaningful progress towards this goal will require expanded efforts to 
reduce the burden and incidence of TB among the foreign-born.  Limited success in 
controlling TB in this group and evidence that the majority of TB cases that arise among 
the foreign-born is attributed to reactivation of infection likely acquired abroad, 
strongly support the need for expanded efforts to conduct post-arrival screening and 
treatment of active TB, as well as LTBI. 
 
The findings of all three studies discussed above suggest that local health department 
efforts to screen and treat foreign-born individuals for tuberculosis and LTBI can be 
effective in reducing the overall burden of illness within the community.  However, 
patients’ compliance with treatment, persistent resource limitations and other factors 
can reduce the effectiveness of these programs.  New approaches are needed to improve 




Patient compliance with LTBI therapies represents a key challenge to reducing 
incidence of TB.  Overall, LTBI treatment completion remains suboptimal.  At BCHD, 
LTBI treatment completion was significantly higher among refugees than other referral 
groups.   Additional efforts are needed to optimize LTBI care at BCHD, and future 
efforts may need to be tailored for different risk groups.  
 
We also found a high prevalence of active TB and LTBI among Class B immigrants 
evaluated by the BCHD-TB program, despite their having thorough pre-departure 
medical examinations. The majority of the active cases did not report any symptoms at 
their pre-departure examination. These findings underscore the need for post-
immigration TB screening for this high risk group despite pre-immigration evaluations, 
and the challenges in diagnosing active TB in a timely fashion.   
 
Though targeted testing and treatment of LTBI in high-risk individuals, such as the 
foreign-born, has been recognized by the Institute of Medicine and the US Centers for 
Disease Control and Prevention as a necessary to achieve U.S. TB elimination goals, it 
remains an overlooked component of TB control efforts in the US.  US immigration 
policies are not sufficient to prevent the introduction of tuberculosis infection into the 
country; therefore, efforts to conduct post-arrival LTBI screening and treatment of the 
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foreign-born are important.  However, competing priorities at public health 
departments, insufficient funding and other operational obstacles have hindered 
progress on this front to-date.  Moreover, future trends, such as an increasing 
proportion of the US population that is foreign born and shifts in the locus of care that 
may result from implementation of the Affordable Care Act are likely to further 
complicate public health departments’ abilities to prioritize LTBI testing and treatment 
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